Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company's drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NYSEMKT:CANF
- CUSIP: N/A
- Web: www.canfite.co.il
- 50 Day Moving Avg: $1.81
- 200 Day Moving Avg: $1.91
- Trailing P/E Ratio: 7.1896
- P/E Growth: 0.0000
- Net Margins: -2,453.03%
- Return on Equity: -57.94%
- Return on Assets: -32.52%
Frequently Asked Questions for Can Fite Biopharma Ltd (NYSEMKT:CANF)
What is Can Fite Biopharma Ltd's stock symbol?
Can Fite Biopharma Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CANF."
How were Can Fite Biopharma Ltd's earnings last quarter?
Can Fite Biopharma Ltd (NYSEMKT:CANF) announced its quarterly earnings results on Tuesday, May, 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. Can Fite Biopharma Ltd had a negative net margin of 2,453.03% and a negative return on equity of 57.94%. View Can Fite Biopharma Ltd's Earnings History.
Where is Can Fite Biopharma Ltd's stock going? Where will Can Fite Biopharma Ltd's stock price be in 2017?
2 brokerages have issued 12-month price targets for Can Fite Biopharma Ltd's shares. Their predictions range from $6.00 to $6.00. On average, they expect Can Fite Biopharma Ltd's share price to reach $6.00 in the next year. View Analyst Ratings for Can Fite Biopharma Ltd.
Who are some of Can Fite Biopharma Ltd's key competitors?
Some companies that are related to Can Fite Biopharma Ltd include XOMA Corporation (XOMA), ContraFect Corporation (CFRX), Aevi Genomic Medicine (GNMX), Trillium Therapeutics (TRIL), Ohr Pharmaceuticals (OHRP), KaloBios Pharmaceuticals (KBIO), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND), Durata Therapeutics (DRTX), Epirus Biopharmaceuticals (EPRS), Idenix Pharmaceuticals (IDIX), InterMune (ITMN), LipoScience (LPDX) and Mast Therapeutics (MSTX).
How do I buy Can Fite Biopharma Ltd stock?
MarketBeat Community Rating for Can Fite Biopharma Ltd (NYSEMKT CANF)MarketBeat's community ratings are surveys of what our community members think about Can Fite Biopharma Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Can Fite Biopharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
Consensus Ratings for Can Fite Biopharma Ltd (NYSEMKT:CANF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$6.00|
Analysts' Ratings History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
(Data available from 7/23/2015 forward)
|10/18/2016||Roth Capital||Reiterated Rating||Buy|
|8/29/2016||Rodman & Renshaw||Initiated Coverage||Buy||$6.00|
|4/4/2016||HC Wainwright||Reiterated Rating||Buy||$6.00|
Earnings History for Can Fite Biopharma Ltd (NYSEMKT:CANF)Earnings History by Quarter for Can Fite Biopharma Ltd (NYSEMKT CANF)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Current Year EPS Consensus Estimate: $-0.31 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS
Dividend History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Latest Headlines for Can Fite Biopharma Ltd (NYSEMKT:CANF)